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Targeting the miR-200c/LIN28B 
axis in acquired EGFR-TKI 
resistance non-small cell lung 
cancer cells harboring EMT features
Hiroki Sato1,*, Kazuhiko Shien1,*, Shuta Tomida2, Kazuhiro Okayasu1, Ken Suzawa1, 
Shinsuke Hashida1, Hidejiro Torigoe1, Mototsugu Watanabe1, Hiromasa Yamamoto1, 
Junichi Soh1, Hiroaki Asano1, Kazunori Tsukuda1, Shinichiro Miyoshi1 & Shinichi Toyooka1,3
MicroRNA (miR)-200 family members (miR-200s) are frequently silenced in advanced cancer and 
have been implicated in the process of epithelial-to-mesenchymal transition (EMT). We previously 
reported that miR-200s were silenced through promoter methylation in acquired EGFR-tyrosine 
kinase inhibitor (TKI) resistant non-small cell lung cancer (NSCLC) cells harboring EMT features. In this 
study, we examined the functional role of miR-200s in NSCLC cells and investigated a novel approach 
to overcoming acquired EGFR-TKI resistance. In the analysis of NSCLC cell lines, each of the miR-
200s expression-silenced cell lines showed promoter methylation. Significant correlations between 
miR-200c silencing and several oncogenic pathway alterations, including EMT-changes and LIN28B 
overexpression, were observed in the database analysis. In addition, EGFR-wild type cell lines had lower 
miR-200s expression levels than EGFR-mutant cell lines. The introduction of miR-200c using pre-miR-
200c caused LIN28B suppression in cells with acquired EGFR-TKI resistance that harbored EMT features. 
Interestingly, both the introduction of miR-200c and the knockdown of LIN28B produced an antitumor 
effect in acquired EGFR-TKI resistance cells, whereas these manipulations were not effective in parental 
cells. The miR-200c/LIN28B axis plays an important role in cells with acquired resistance to EGFR-TKI 
that harbor EMT features and might be a useful therapeutic target for overcoming resistance.
The prognosis of advanced non-small cell lung cancer (NSCLC) patients remains unsatisfactory, despite improve-
ments in diagnosis and therapeutic strategies. A considerable number of advanced NSCLC patients are not sen-
sitive to treatment, and their tumors frequently develop drug resistance, usually leading to a relapse and cancer 
death. In 2004, mutations in the epidermal growth factor receptor (EGFR) gene that cause oncogene addic-
tion to EGFR were discovered in NSCLC1,2. EGFR-tyrosine kinase inhibitors (TKIs) have exhibited significant 
effects against NSCLC with EGFR mutations3–5, however, patients who initially respond to EGFR-TKIs eventually 
acquire resistance, which is a critical problem in the treatment of patients with advanced NSCLC. Several mech-
anisms are believed to be responsible for acquired EGFR-TKIs resistance. Secondary EGFR T790M and MET 
amplification may together account for 70% of this resistance, and activation of the MET/HGF axis, leading to the 
acquisition of an epithelial-to-mesenchymal transition (EMT) signature, and transformation from NSCLC into 
small cell lung cancer have also been reported as possible mechanisms of acquired resistance to EGFR-TKIs in 
NSCLC6–11. Among these mechanisms, an EMT is negatively associated with EGFR-TKI sensitivity in NSCLC12,13. 
The activation of several pathways and molecules, including TGF-β -IL-6, Slug, Notch-1, PDGFR, ZEB1, Axl, and 
MED12, is reportedly associated with acquired EGFR-TKI resistance in cells with EMT features14. In addition, 
we previously reported a relation between epigenetic alteration related to EMT and EGFR-TKI resistance15. We 
have also demonstrated the CpG island hypermethylation-associated silencing of microRNA (miR)-200 family 
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members in acquired EGFR-TKI resistance cells with EMT features. However, the detailed mechanisms underly-
ing the EMT-related acquired resistance to EGFR-TKIs remains unclear.
MicroRNAs are small noncoding, endogenous, single-stranded RNAs that are commonly deregulated in 
human cancers. Several miRs show abnormal expression patterns in cancers with consequent alteration of the 
target oncogenes or tumor suppressor genes16. MicroRNA profiling for NSCLC has been previously conducted 
by several groups to predict patient survival17–19. These profiles have also been correlated with clinicopathological 
parameters of NSCLC patients20,21. Bishop et al. used this approach for classification of NSCLC22. Among such 
miRs, miR-200 family members (miR-200s: miR-200a, 200b, 200c, 141, and 429) have been reported to play 
important roles in the progression of NSCLC23,24. MiR-200s are genetically grouped in two polycistronic units: 
miR-200b/200a/429 (miR-200ba429) and miR-200c/141 (miR-200c141), clustered in chromosomes 1 and 12, 
respectively24. They are frequently silenced in advanced cancer and have been implicated in EMT and tumor inva-
sion through the targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB225. ZEB1 is also known to 
repress miR-200s transcription in a negative feedback loop. MiR-200c silencing was also reported in cancer stem 
cells (CSCs), suggesting that miR-200c deregulation is a key event in multiple levels of tumor biology26.
Several of the miRs identified from these studies have been associated with key regulatory pathways including 
EGFR and KRAS in NSCLC. In this study, we examined the functional role of miR-200s in NSCLC cell lines, 
and investigated the mechanisms underlying the EMT and acquired EGFR-TKI resistance to develop a novel 
approach for overcoming acquired resistance to EGFR-TKIs in NSCLC.
Results
Expression and methylation statuses of miR-200s in NSCLC. The miR-200s expression statuses 
determined using quantitative reverse transcription-PCR (qRT-PCR) and the methylation statuses determined 
using methylation-specific PCR (MSP) in 34 NSCLC cell lines and the bronchial epithelial cell line HBEC-5KT 
are shown in Fig. 1. MiR-200ba429 and miR-200c141 were unmethylated in HBEC-5KT, and the miR-200s 
expression level in HBEC-5KT was used as a control. In the NSCLC cell lines, mir-200ba429 was methylated 
in 13 (38%), partially methylated in 8 (24%), and unmethylated in 13 (38%) cell lines. MiR-200c141 was meth-
ylated in 10 (29%), partially methylated in 8 (24%), and unmethylated in 16 (47%) cell lines. We found that the 
expression of miR-200s was silenced in most of the methylated or partially methylated cell lines. We treated 6 cell 
lines (3 unmethylated and 3 methylated) with the DNA-demethylating agent 5-aza-2-deoxycytidine (5-Aza) and 
found that the miR-200s expression levels were restored after treatment with 5-Aza in miR-200s-methylated cells 
(Supplementary Fig. S1), suggesting that the miR-200s expression levels were regulated by promoter methylation.
Functional analysis of miR-200s in NSCLC cells. To define the functional significance of genes regu-
lated by the miR-200c status, we performed a gene set enrichment analysis (GSEA) using the Cancer Cell Line 
Encyclopedia (CCLE) database. Among 34 NSCLC cell lines, comprehensive gene expression data for 28 cell 
lines were available in the CCLE database, and these cell lines were categorized into an miR-200c-low group 
Figure 1. Expression and methylation statuses of miR-200s in 34 NSCLC cell lines and HBEC-5KT. The 
miR-200a, miR-200b, and miR-200c expression statuses as determined using qRT-PCR and the miR-200ba429 
and miR-200c141 methylation statuses as determined using methylation-specific PCR (MSP) in 34 NSCLC cell 
lines and HBEC-5KT are shown. The miR-200s expression levels in HBEC-5KT were set at 1, and the expression 
levels in the NSCLC cells were shown relative to those in the HBEC-5KT cell line. For the MSP assay, each circle 
represents the promoter methylation status (white circle, unmethylated; gray circle, partially methylated; black 
circle, methylated).
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(n = 16) and an miR-200c-high group (n = 12) based on the miR-200c expression and methylation status 
(Supplementary Table S1). We found that several pathways, including genes defining an EMT (HALLMARK_
EPITHELIAL_MESENCHYMAL_TRANSITION), and a subgroup of genes regulated by Myc (HALLMARK_
MYC_TARGETS_V1), were positively enriched in the miR-200c-low group (Table 1). We then comprehensively 
analyzed the correlation between miR-200c expression and the gene expression status (Supplementary Table S2). 
The epithelial marker CDH1 was positively correlated with miR-200c expressions (Pearson r = 0.70, P < 0.0001) 
(Fig. 2A), and the mesenchymal marker ZEB1 was negatively correlated (Pearson r = − 0.66, P < 0.0001) (Fig. 2B). 
Interestingly, LIN28B, an oncogenic stem-cell factor27, showed a negative correlation with miR-200c expression 
GSEA Pathway (miR-200c low group, n = 16) ES* FDR* q-val
HALLMARK_SPERMATOGENESIS 0.44 0.322
HALLMARK_PANCREAS_BETA_CELLS 0.48 0.805
HALLMARK_MYC_TARGETS_V1 0.26 0.571
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 0.54 0.593
HALLMARK_E2F_TARGETS 0.36 0.687
HALLMARK_ANGIOGENESIS 0.47 0.636
GSEA Pathway (miR-200c high group, n = 12) ES FDR q-val
HALLMARK_CHOLESTEROL_HOMEOSTASIS − 0.67 0.204
HALLMARK_ANDROGEN_RESPONSE − 0.59 0.77
HALLMARK_NOTCH_SIGNALING − 0.52 0.573
HALLMARK_ESTROGEN_RESPONSE_LATE − 0.5 0.44
HALLMARK_APICAL_JUNCTION − 0.37 0.448
HALLMARK_P53_PATHWAY − 0.52 0.415
Table 1. Enriched pathways in the cells with miR-200c-low as well as miR-200c-high expression.  ES: 
enriched score. FDR: False discovery rate.
Figure 2. Functional analysis of miR-200s in NSCLC cells. (A) Correlation between the miR-200c expression 
level and CDH1 expression in 28 NSCLC cell lines. Each circle represents NSCLC cell lines. Closed circle, 
miR-200c low expression group ; Opened circle, miR-200c high expression group. (B) Correlation between 
the miR-200c expression level and ZEB1 expression in 28 NSCLC cell lines. (C) Correlation between the miR-
200c expression level and LIN28B expression in 28 NSCLC cell lines. (D) Correlation between EGFR-mutation 
statuses and miR-200s expressions in 34 NSCLC cell lines. WT, wild type; mut, mutation.
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to the same extent as the correlation between CDH1 or ZEB1 and miR-200c (Pearson r = − 0.73, p < 0.0001) 
(Fig. 2C). In western blots of 34 NSCLC cell lines and HBEC-5KT, miR-200c-silenced NSCLC cells exhibited a 
low E-cadherin expression level and high vimentin or ZEB1 expression levels (Supplementary Fig. S2). We also 
investigated the correlation between miR-200s and EMT markers in breast cancer, colon cancer and gastric can-
cer cell lines. As shown in Supplementary Fig. S3, in all three carcinomas, the expression of miR-200s was low in 
the cell lines harboring EMT features. These findings are presumed to supplement the relevance of this miR-200c 
expression based classification and importance of LIN28B.
Associations between miR-200c statuses and oncogenic alterations. Among the 34 NSCLC cell 
lines that were examined, 10 cell lines harbored an EGFR mutation (EGFR-mut), 7 cell lines harbored a KRAS 
mutation (KRAS-mut), 4 cell lines harbored a BRAF mutation (BRAF-mut), 1 cell line harbored a HER2 muta-
tion (HER2-mut), 1 cell line harbored an NRAS mutation (NRAS-mut), and 11 cell lines harbored none of these 
mutations (Supplementary Table S1). In 10 cell lines with EGFR-mut, miR-200ba429 and miR-200c141 were 
unmethylated in 8 cell lines and partially methylated in 2 cell lines (HCC2279 and H1650) (Table S1). In addition, 
the miR-200s expression levels were significantly higher in the EGFR-mut cell lines than in the EGFR wild-type 
cell lines (Fig. 2D; P = 0.037 in miR-200a, P = 0.034 in miR-200b, and P = 0.0054 in miR-200c). The similar ten-
dency was observed in 28 NSCLC cell lines which were examined by GSEA (Supplementary Table S3; P = 0.044).
MiR-200c introduction showed an antitumor effect in cells with acquired EGFR-TKI resistance. 
As we previously reported, EMT features are correlated with the acquisition of EGFR-TKI resistance, but the 
mechanisms responsible for EGFR-TKI resistance remain unclear. We utilized experimentally established cells 
with acquired EGFR-TKI resistance and EMT features. By continuously exposing the cells to gefitinib, we estab-
lished the EGFR-TKI-resistant clones HCC4006-GR-step and HCC4006-GR-high from the EGFR-mut HCC4006 
cell line15. The established cell line showed EMT features, while lacking both T790M secondary EGFR-mut 
and MET-amplification. The IC values against gefitinib determined using an MTS assay was 0.024 μ mol/L for 
HCC4006 and over 10 μ mol/L for HCC4006-GR cells. MiR-200s expression was suppressed in HCC4006-GR 
cells compared with the parental HCC4006 (Fig. 3A). In western blots, the HCC4006-GR cells showed EMT 
features with the downregulation of E-cadherin and the upregulation of N-cadherin, vimentin, and ZEB-1 
compared with HCC4006 (Fig. 3B). We examined the effect of miR-200s introduction against cell viability in 
HCC4006 and HCC4006-GR-high. Although the cell viability of HCC4006 was not affected by miR-200c intro-
duction, the cell viability of HCC4006-GR cells was highly suppressed by miR-200c introduction (Fig. 3C and 
Supplementary Fig. S3).
MiR-200c introduction suppressed LIN28B expression and produced an antitumor effect in 
EGFR-TKI resistant cells. From the database analysis, miR-200c silencing was found to be correlated 
with the upregulation of LIN28B. Indeed, LIN28B was upregulated in HCC4006-GR cells, compared with that 
in HCC4006, as determined using qRT-PCR (Fig. 4A). When we introduced miR-200c into HCC4006 and 
HCC4006-GR cells, the expressions of not only mesenchymal protein ZEB1, but also LIN28B were significantly 
suppressed. On the other hand, expression of E-cadherin, which is known as an epithelial marker, was induced in 
HCC4006-GR cells (Fig. 4B).
Knockdown of LIN28B suppressed cell viability in cells with acquired EGFR-TKI resistance. To 
examine the role of LIN28B on cell survival in cells with acquired EGFR-TKI resistance and EMT features, we 
suppressed the expression of LIN28B using two kinds of si-RNA. Interestingly, LIN28B suppression using siRNA 
produced an antitumor effect in HCC4006-GR cells, whereas it was not effective in HCC4006 cells when eval-
uated using the tetrazolium salt, 3-4,5 dimethylthiazol-2,5 diphenyl tetrazolium bromide (MTT) (Fig. 5A). In 
a western blot analysis, the knockdown of LIN28B led to the expression of the apoptosis marker c-PARP in 
HCC4006-GR cells (Fig. 5B). Regarding EMT features, In HCC4006-GR cells, even though the difference is not 
so clear, the knockdown of LIN28B seems to induce the E-cadherin expression and to reduce the vimentin and 
ZEB1 expression. This result suggests the possibility that LIN28B is one of the mediator of epithelial to mesen-
chymal transition in TKI resistance cell line. In addition, we examined phosphorylation of STAT3 as an indicator 
of TGF-beta/IL6 pathway. As a result, the knockdown of LIN28B doesn’t seem to affect the phosphorylation of 
STAT3, suggesting that LIN28B doesn’t regulate TGF-beta/IL6 pathway.
MiR-200c downregulation and LIN28B upregulation after EGFR-TKI resistance acquisition on 
NSCLC tissues. We randomly selected the 3 non-small cell lung cancer patients who were treated at our hos-
pital. All 3 patients underwent pulmonary resection as an initial treatment. After relapse, they were treated with 
EGFR-TKI and acquired resistance finally. We investigated the alteration of EMT marker and the expression of 
LIN28B and miR-200c before and after EGFR-TKI treatment. The alteration of e-cadherin, vimentin and LIN28B 
was analyzed by immunohistochemistry and that of miR-200c was analyzed by qRT-PCR. As a result, we con-
firmed that the expression of miR-200c was significantly suppressed, compared to its expression before resistance 
acquisition in all three patients (Fig. 6A). On the other hand, LIN28B was highly expressed, compared to before 
resistance acquisition (Fig. 6B). And then, the expression of E-cadherin was reduced and that of vimentin was 
increased, indicating that tumors acquired the EMT feature in the process of EGFR-TKI resistance acquisition 
(Fig. 6B). These results were consistent with those of HCC4006 parental and GR cells.
Discussion
In this study, we found that the miR-200c/LIN28B axis plays a critical role in the cell viability of acquired 
EGFR-TKI resistance cells harboring EMT features. Acquired resistance cells showed miR-200s silencing 
and LIN28B overexpression, which was the same for clinical samples. MiR-200c introduction caused LIN28B 
www.nature.com/scientificreports/
5Scientific RepoRts | 7:40847 | DOI: 10.1038/srep40847
suppression, and both miR-200c introduction and LIN28B suppression had an anti-proliferative effect in 
HCC4006-GR cells. These effects were not observed in parental HCC4006 cells lacking miR-200s silencing 
and LIN28B overexpression, suggesting that the survival of acquired resistance cells depends on the miR-200c/
LIN28B axis (Fig. 5C). It is still inconclusive that miR-200c directly or indirectly regulates LIN28B. Therefore, 
further investigation is mandatory.
We found that miR-200c expression was not silenced in most of the EGFR-mut NSCLC cell lines. Several 
reports have shown that EGFR-mut is associated with epithelial characteristics in NSCLC28,29. The detailed mech-
anisms of how EGFR-mut leads to the maintenance of epithelial characteristics have been unclear. Takeyama 
et al. hypothesized that EGFR-mut cells are resistant to EMT-inducing signals, or that EGFR-mut cells specifically 
express genes that retain cells in the epithelial state29. On the other hand, several reports have shown that the 
chronic activation of EGFR can promote an EMT-like change30,31. Further investigation is required regarding 
EGFR-mut and epithelial characteristics, including E-cadherin expression, because E-cadherin expression has 
been proposed as a biomarker predicting the clinical activity of EGFR-TKIs in NSCLC12.
We and other groups have reported that EGFR-TKIs cause an EMT change with miR-200s silencing in a sub-
set of NSCLC harboring EGFR-mut14. EMT is a phenomenon in which cells with epithelial phenotypes acquire 
mesenchymal characteristics, and EMT plays an important role in cancer metastasis and drug resistance. EMT 
has been shown to be correlated with a poor prognosis in multiple epithelial-derived solid tumors. In preclini-
cal models and clinical samples, EMT features were observed after the acquisition of resistance to EGFR-TKIs. 
Although the detailed mechanisms explaining how these alterations cause EGFR-TKIs resistance have been 
unclear, we have identified LIN28B as a candidate oncogenic driver molecule in acquired EGFR-TKI resistance 
cells.
LIN28B and its paralog LIN28A are RNA-binding proteins that mediate diverse biological functions. The 
LIN28 family regulates mammalian stem cell self-renewal, and LIN28A in combination with NANOG, OCT4, 
and SOX2, can reprogram human somatic cells to become pluripotent stem cells32. LIN28A participates in these 
Figure 3. Antitumor effect of miR-200c introduction in parental and acquired EGFR-TKI resistance cells. 
(A) Relative miR-200c expression level using qRT-PCR in parental HCC4006 cells and acquired EGFR-TKI-
resistant HCC4006-GR cells. (B) EMT-related protein expression level using western blotting in HCC4006 and 
HCC4006-GR cells. The blots of whole membrane are presented in Supplementary Fig. S5. (C) Cell viability 
after miR-200c transfection in HCC4006 and HCC4006-GR cells using MTT assay.
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key biological processes by blocking the maturation of the tumor suppressor miR let-7 family33,34. Furthermore, 
LIN28A plays a functional role in the maintenance of the ALDH1-positive CSC population in tumors35. LIN28B 
also influences multiple oncogenic signaling networks in diverse cellular contexts, and is being recognized as 
oncogenic stem-cell factor27,36. Indeed, CD166-positive tumor-initiating cells obtained from primary NSCLC 
tumor expressed high levels of LIN28B27. In addition, LIN28B has been reported as a candidate biomarkers of 
resistance to platinum-based chemotherapy and of a poor clinical outcome in patients with epithelial ovarian 
carcinoma37, suggesting the function of LIN28B as a drug-resistant factor.
LIN28B expression is reportedly induced by the c-Myc oncogenic transcription factor in multiple human and 
mouse tumor models38. The upregulation of LIN28 family and Myc or the downregulation of let-7 may promote 
the conversion of epithelial cells to a more undifferentiated stage and maintain the tumor cells in this stem-like 
stage35,38. In our analysis, genes regulated by Myc were positively enriched in the miR-200c-low group when 
examined using GESA (Table 1). These findings are compatible with the result that miR-200c-silenced cells had a 
high level of LIN28B expression as well as EMT features.
MiR-200c-introduced cells showed the downregulation of LIN28B in NSCLC cells, and miR-200c introduc-
tion produced an anti-proliferative effect in HCC4006-GR cells. In addition, both miR-200c introduction and 
LIN28B downregulation inhibit the expression of EMT markers. In prostate cancer, Kong et al. also reported 
that miR-200b and miR-200c introduction downregulated the LIN28B protein39. Although the exact mechanism 
involving the miR-200s and LIN28B interaction remains unclear, it is possible that both the miR-200s and the 
let-7 miR families are composed of multiple members, with each member regulating largely overlapping sets of 
targets40.
In conclusion, the miR-200c/LIN28B axis plays an important role in acquired resistance to EGFR-TKI and 
might be a useful therapeutic target for overcoming EMT-related EGFR-TKI resistance. To date, there are no 
drugs directly targeting miR-200c or LIN28B expression. Further investigation of the modulation of the miR-
200c/LIN28B axis may lead to further successes in EGFR-TKIs treatment.
Materials and Methods
Ethics statement. This study was approved by the Institutional Review Board/Ethical Committee of 
Okayama University and all experiments were performed in accordance with relevant guidelines and regulations.
Cell lines and reagents. We used 34 human NSCLC cell lines, 4 breast cancer cell lines, 3 colon can-
cer cell lines, 4 gastric cancer cell lines, 1 bronchial epithelial cell line (HBEC-5KT), and 1 embryonic kid-
ney cell line (HEK293T). The details of 34 NSCLC cell lines and 1 bronchial epithelial cell line are shown in 
Supplementary Table S1. All cell lines except for PC-9 and A549 were kindly provided by Dr. Adi F. Gazdar 
(Hamon Center for Therapeutic Oncology Research and Department of Pathology, University of Texas 
Southwestern Medical Center, Dallas, TX). PC-9 was obtained from Immuno-Biological Laboratories (Takasaki, 
Gunma, Japan). A549 was obtained from the American Type Culture Collection (Manassas, VA). All the 
NSCLC cell lines except for H3255 were maintained in RPMI-1640 (Thermo Fisher Scientific, Waltham, MA) 
supplemented with 10% fetal bovine serum (FBS). H3255 was maintained in ACL-4. HEK293T cells were 
cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% FBS. HBEC5-KT was maintained in 
Keratinocyte-SFM medium with bovine pituitary extract and human recombinant epidermal growth factor (all 
Figure 4. Forced miR-200c expression leads to suppression of LIN28B expression. (A) LIN28 expression 
level as determined using qRT-PCR in HCC4006 and HCC4006-GR cells. ND, not-determined. The LIN28B 
expression level in H1299 was set at 1, and the relative expression levels in HCC4006 parental and resistance 
cell lines were shown. (B) EMT-related proteins and LIN28B expression level using western blotting after pre-
miR-200c or miR-Scramble transfection in HCC4006 and HCC4006-GR cells. The blots of whole membrane are 
presented in Supplementary Fig. S5.
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from Thermo Fisher Scientific)41. In addition, we used an experimentally established EGFR-TKI resistant cell line 
with an EGFR activation mutations (19del), HCC4006-GR-step and HCC4006-GR-high, as previously reported15. 
The identities of all the cell lines were confirmed by analyzing the short tandem repeat profile using the Cell ID 
System (Promega, Madison, WI) and an ABI Prism 310 Genetic Analyzer (Thermo Fisher Scientific), according 
to the manufacturer’s instructions. The EGFR-TKI gefitinib was purchased from InvivoGen (San Diego, CA).
DNA, RNA and miRNA extraction. Genomic DNAs were extracted from cell lines using a DNeasy Blood 
and Tissue Kit (Qiagen, Venlo, Netherlands). Total RNAs were extracted from cell lines using an RNeasy Mini 
Kit (Qiagen). Complementary DNA (cDNA) was synthesized from the total RNA using High-Capacity cDNA 
Reverse Transcription Kits (Thermo Fisher Scientific), according to the manufacturer’s instructions. The miRNA 
was isolate from cell lines with TaqMan MicroRNA Cells-to-CT Kit (Ambion) and total RNA was extracted 
from microdissected formalin-fixed, paraffin-embedded (FFPE) tissues by using a miRNeasy FFPE Kit (Qiagen). 
Reverse transcription was conducted with TaqMan Micro-RNA Reverse Transcriptional Kit systems (Applied 
Biosystems).
DNA direct sequencing and methylation analysis. We determined the mutational status of EGFR, 
HER2, KRAS, NRAS, and BRAF genes in NSCLC cell lines using direct sequencing, as previously reported15. In a 
methylation analysis, DNA was subjected to bisulfate treatment using the Epitect Bisulfite Kit (Qiagen), accord-
ing to the manufacturer’s protocol. The DNA methylation statuses of miR-200ba429 and miR-200c141 were 
examined using MSP, as previously reported (Supplementary Table S4A)15. To restore the gene expression that 
was reduced by methylation, cells were treated with 5-Aza (Sigma-Aldrich, St. Louis, MO) at a concentration of 
5 μ mol/L for 6 days.
mRNA and miRNA expression analysis using quantitative reverse transcription-PCR. Gene 
expression was analyzed using qRT-PCR and cDNAs, TaqMan Gene Expression Assays, and the ABI StepOnePlus 
Figure 5. Antitumor effect of LIN28B knockdown in parental and acquired EGFR-TKI resistance cells.  
(A) Cell viability after LIN28B knockdown in HCC4006 and HCC4006-GR cells as determined using an 
MTT assay. (B) Expression of the apoptosis marker c-PARP and EMT marker after LIN28B knockdown as 
determined using western blotting. The blots of whole membrane are presented in Supplementary Fig. S5.  
(C) Diagram of the mechanism of the EGFR-TKI-mediated miR-200s/LIN28B interaction causing an EMT and 
acquired EGFR-TKI resistance in EGFR-mut NSCLC cells.
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Real-Time PCR Instrument (Thermo Fisher Scientific). The expressions of mRNA and miR were calculated using 
the delta-delta-CT method. The glyceraldehyde-3-phosphate dehydrogenase gene and miR-374 were used as 
endogenous controls for the mRNA and miR expression analyses, respectively. The primer and probe sets were 
purchased from Thermo Fisher Scientific and were used according to the manufacturer’s instructions (Table S4B).
Gene expression analysis in CCLE cell line panel and functional analysis in GSEA. Comprehensive 
gene expression data for 28 NSCLC cell lines were obtained from the CCLE (http://www.broadinstitute.org/
ccle/)42. Twenty-eight NSCLC cell lines were categorized into a miR-200c low group (n = 16) or a miR-200c high 
group (n = 12) based on the miR-200c expression level and methylation status, and functional analyses of the 
NSCLC cell lines were performed using GSEA (Molecular Signatures Database v5.0)43.
Western blotting analysis. The detailed protocol for western blotting has been described previously44. The 
primary antibodies were as follows: anti-E-cadherin, N-cadherin, EGFR, EGFR-19del (exon19 E746-A750del 
specific), vimentin (R28), LIN28B (Cell Signaling Technology, Beverly, MA), and ZEB1 (H-102, Santa Cruz 
Biotechnology, Santa Cruz, CA). Monoclonal anti-actin antibody, used as an equal loading control, was pur-
chased from Merck Millipore (Billerica, MA). The following secondary antibodies were used: goat anti-rabbit 
or anti-mouse immunoglobulin G (IgG)-conjugated horseradish peroxidase (Santa Cruz Biotechnology). To 
detect specific signals, the membranes were examined using ECL Prime Western Blotting Detection System (GE 
Healthcare, Amersham, UK).
Pre-miRNA transfection. NSCLC cells were transfected with 50 nmol/L of pre–miR-200c (has-miR-
200c-3p, #MC11714) or control-miR (miR-Scrambled) using Lipofectamine RNAiMAX (all from Thermo Fisher 
Scientific), total amount of miR-mimics was 300 pmol, once a day for 2 days. The cells were used in the assays at 
48 hours after the final transfection.
SiRNA transfection. NSCLC cells were transfected with 5 nmol/L of Silencer Select siRNA against LIN28B 
(si-LIN28B#1 and si-LIN28B#2) or scrambled negative control siRNA (si-Scramble) (Thermo Fisher Scientific) 
by using Lipofectamine RNAiMAX and were incubated for 48 hours.
Determination of cell proliferation. The IC50 value against gefitinib was determined using a modified 
MTS assay with CellTiter 96 AQueous One Solution Reagent (Promega) as previously reported15. For exper-
iments testing the effect of miR-200c transfection or the knockdown of siRNA on cell proliferation, the MTT 
(Sigma-Aldrich, St. Louis, MO) dye reduction method was used. Cells were cultured at 37 °C with 5% CO2, in 
6-well plates at a concentration of 1 × 105 cells/mL for 72–96 h. MTT was dissolved in RPMI-1640, and 100 μL 
of the MTT solution were added to each well; the plates were then incubated at 37 °C with 5% CO2 for 2 h. 
Subsequently, 100 μ L of dimethyl sulfoxide were added to each well. The cell viability was assessed by measuring 
Figure 6. MiR-200c downregulation and LIN28B upregulation after EGFR-TKI resistance acquisition  
on NSCLC tissues. (A) Mir-200c expression level as determined using qRT-PCR in NSCLC patients.  
(B) E-cadherin, vimentin and LIN28B expression level as determined by immunohistochemistry. The images  
of a representative patient are shown.
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the optical density at 570 nm and 690 nm on a plate reader. Three independent experiments consisting of triplicate 
runs (at least) were performed.
Immunohistochemical analysis of clinical samples. Lung cancer tissues were obtained from the 
patients who underwent surgery at Okayama University Hospital (Okayama, Japan). This experimental proto-
col was approved by the Institutional Review Board/Ethical Committee of Okayama University (No. 147) and 
informed consent were obtained from all the patients. Tissue samples were fixed in 10% formaldehyde and 
embedded in paraffin.
Immunohistochemical (IHC) staining with E-cadherin (diluted 1:1000 in PBS), vimentin (1:200), LIN28B 
(1:100) was conducted. The detailed protocol for the IHC staining has been described previously45.
Statistical analyses. All the statistical analyses were performed using GraphPad Prism 6 (GraphPad 
Software). P < 0.05 was considered statistically significant. All the tests were two-sided.
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